Uptake of the Pfizer antiviral has remained stubbornly low since it transitioned to the commercial market in the fall, in part because of patients sometimes being charged up to the full list price of $1,400.
"Our focus is ensuring patients have access to this important treatment and we are committed to ensuring eligible patients have a $0 co-pay," a Walgreens spokesperson said.
[
add
]
[
|
|
...
]